Clinical Trials · NCT01658501
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- PhaseBio Pharmaceuticals Inc.
- Enrollment
- 593
- Start date
- Jul 2012
- Locations
- 93 sites, United States
- Primary endpoint
- Evaluation of dose response of Glymera as measured as the change from baseline in HbA1c after 20 weeks of dosing with Glymera compared to placebo and active comparator